NasdaqGM:ZLABBiotechs
Zai Lab (ZLAB) Stock Could Be 47.5% Undervalued After China Approved TIVDAK
Zai Lab (ZLAB) stock is in focus after China’s National Medical Products Administration approved TIVDAK for adults with recurrent or metastatic cervical cancer whose disease progressed on or after chemotherapy.
See our latest analysis for Zai Lab.
The NMPA approval for TIVDAK comes after a mixed stretch for Zai Lab, with the stock showing a 1-day share price return of 3.87% and a 7-day share price return of 7.58%, yet a 1-year total shareholder return that declined 56.36%. This suggests...